NASDAQ · Biotechnology

Abivax S.A. (ABVX) Stock

$136.94 +1.50% NASDAQ: ABVX Healthcare

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.

Valuation

MetricValue
Price$136.94
Market Cap$10.06B
P/E Ratio-24.37
P/B Ratio17.98
P/S Ratio0.00
EPS (TTM)$-4.65
52-Week High$148.83
52-Week Low$9.25
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-165.19%
ROA-57.52%
ROCE-48.08%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.10
Current Ratio8.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-41.0M$-65.0M$-127.0M$-173.0M$-246.0M
Net Profit$-42.0M$-61.0M$-148.0M$-176.0M$-336.0M
EPS$-2.75$-3.18$-3.43$-2.80$-4.65
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$109.0M$76.0M$327.0M$205.0M$584.0M
Total Liabilities$83.0M$68.0M$131.0M$165.0M$129.0M
Cash$61.0M$27.0M$252.0M$144.0M$516.0M
Borrowings$52.0M$39.0M$58.0M$97.0M$46.0M

Latest News

Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update Business Wire · Jul 16, 2026 Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross? Zacks · Jul 10, 2026 Abivax CEO says $920M raise funds U.S. drug launch without Big Pharma Quartz · Jul 10, 2026 3 Soaring Stocks That May Have More Upside Ahead Motley Fool · Jul 7, 2026 Abivax: Wall Street Catches Up to the Data MarketBeat · Jul 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-46.0M$-54.0M$-100.0M$-154.0M$-156.0M
Investing Cash Flow$-3.0M$-12.0M$-11.0M$15.0M$-13.0M
Financing Cash Flow$-10.0M$-4.0M$-28.0M$-10.0M$-1.0M
Net Cash Flow$31.0M$-34.0M$225.0M$-108.0M$389.0M
Free Cash Flow$-47.0M$-54.0M$-100.0M$-155.0M$-156.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.40
EV / EBITDA-32.75
FCF Yield-1.88%
Quick Ratio8.75
Interest Coverage-8.79
Return 1Y1222.39%
Return 3Y—
Return 5Y—

Ownership

Insiders Held0.00%
Institutions Held70.62%
Institutions Float Held70.62%
Institutional HolderSharesReport Date
TCG Crossover Management, LLC6,481,0852026-03-31
UBS Group AG4,547,4062026-03-31
Darwin Global Management, Ltd.3,468,6572026-03-31
Morgan Stanley1,704,9582026-03-31
Vestal Point Capital, LP1,500,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AXSM $238.37 -1.09% 38.05 $12.27B 0.00%
CORT $91.12 -4.45% 146.17 $9.78B 0.00%
CYTKCytokinetics, Incorporated $80.62 -0.15% -11.82 $10.03B 0.00%
HALO $81.48 -0.55% 23.58 $9.66B 0.00%
JAZZJazz Pharmaceuticals plc $258.38 +0.94% 2071.27 $16.23B 0.00%

About Abivax S.A.

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

Abivax S.A. is headquartered in FR.

Abivax S.A. (ABVX) stock trades at $136.94 with a market capitalization of $10.06B. The stock is valued at a price-to-earnings (P/E) ratio of -24.37, price-to-book of 17.98, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $9.25 and $148.83, and currently trades 8.0% below its 52-week high.

On profitability, Abivax S.A. generates a return on equity (ROE) of -165.19%, return on capital employed of -48.08%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.abivax.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides